Anika Therapeutics completes sale of Arthrosurface for $10M; plans to divest Parcus Medical

Anika Therapeutics, Inc.

Sold Arthrosurface to Phoenix Brio for $7M note plus up to $3M contingent consideration based on sales performance.
Announced intention to sell Parcus Medical sports medicine business as part of strategic review.
Focus shifts to core hyaluronic acid (HA) products and Regenerative Solutions, targeting $4B global market.
Piper Sandler serving as exclusive financial advisor for both the Arthrosurface sale and potential Parcus divestiture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.